Savonix Announces First-of-its-Kind Digital Cognitive Assessment; Calls for Beta Testers
The company democratizing neuroscience opens program testing for
Savonix Mobile, available for iOS and Android devices
SAN FRANCISCO–(BUSINESS WIRE)–Savonix, the company revolutionizing access to brain data, launches
today the open beta of the world’s first fully mobile, clinically valid
digital neuro-cognitive assessment, Savonix Mobile. The state-of-the-art
cognitive and emotional function evaluation provides an accurate,
accessible, actionable and affordable tool for professional cognitive
screening. Led by former Stanford Medical healthcare professionals, and
built using the published data from decades of clinical trials research
in cognitive assessment, Savonix is the only mobile evidence-based,
digital cognitive assessment on the market.
Following a two month closed beta with select industry leaders, Savonix
is opening the fully-functioning application to consumers for a six week
open beta to receive user feedback. Users download the application for
free in the Apple App Store or Google Play, register for a login and
access key on the Savonix website,
and proceed to complete the assessment and receive their results via the
mobile application. Following the close of the open beta, Savonix will
remain in the app stores available exclusively to end users via Savonix
licenses with healthcare organizations.
Until Savonix, cognitive assessment remained locked inside dated,
analogue processes that are costly, time consuming and only accessible
through a clinician. The test, which is used for screening cognitive and
emotional function, is accessible via any iOS or Android device during
the open beta. Users can take the set of clinically valid
neuro-cognitive tests to receive results in multiple domains, such as:
- Verbal memory
- Impulse control
- Sustained attention
- Information processing speed
- Cognitive flexibility
- Emotionality
- Working memory
- Executive function
- Emotion regulation
- Decision making
Suitable for children, adults and older adults, the assessment takes an
average of 30 minutes to complete. For companies and clinicians using
the tool, Savonix provides full individual and group level reports,
analysis and data to improve patient outcomes in a variety of health
problems. During the limited time open beta, independent users receive
their results in the mobile application, which they can present to a
clinician for additional evaluation and diagnoses.
“We are unleashing the power of neurocognitive assessment by making it
affordable and widely accessible, in the palm your hand,” says Savonix
founder Mylea Charvat, Ph.D. “The platform has already demonstrated
great value to beta users by providing a quick and accurate evaluation
of neuro-cognitive function.”
The primary focus of the open beta program will be soliciting feedback
on user experience. To date, key upgrades from the closed beta include:
- Superior images to increase task comprehension
- Improved error messaging for incorrect data inputs
- In-app notifications when the user is out of network or Wi-Fi range
- Countdown bar for percent complete
- Improved responsiveness to tap and point-and-drag functionality
-
User interface improvements including colors, button messages and
timing of screen transitions
Visit the App
Store or Google
Play to download the application.
About Savonix
Savonix is neuroscience democratized. Its digital, research-based
assessment delivers a state-of-the-art cognitive and emotional function
evaluation. The evidence-based screening is a 30-minute (on average)
assessment accessed from any iOS or Android device. Savonix Mobile is an
accurate, accessible, actionable and affordable tool for professional
cognitive screening. Savonix raised $1.5 million in seed round funding,
led by RoundGlass Partners, with Kickstart Seed Fund, BMNT capital and
angel investors Bandel Carano and Ed Glassmeyere in October 2015.
Dr. Mylea Charvat is a translational neuroscientist, entrepreneur, and
the CEO and founder of Savonix. She completed her Ph.D. Fellowship in
Clinical Neuroscience at Stanford School of Medicine after receiving her
Ph.D. in clinical psychology from Palo Alto University. Empowered by her
passion to make access to cognitive screens easy and affordable, Mylea
transitioned out of her clinical and academic role to begin the
development of Savonix in 2014.
To learn more about Savonix and the mobile assessment, visit www.Savonix.com.
Contacts
BAM Communications
Emily Webb, 619-855-7230
Emily@bamcommunications.biz
